Vaginal microbicide and diaphragm use for sexually transmitted infection prevention: A randomized acceptability and feasibility study among high-risk women in madagascar

Sexually Transmitted Diseases

Volumn 35, Issue 9, 2008, Pages 818-826

  Behets, Frieda M ^a,b   Turner, Abigail Norris ^a   Van Damme, Kathleen ^a,b,c   Rabenja, Ny Lovaniaina ^b   Ravelomanana, Noro ^c   Swezey, Teresa A ^a   Bell, April J ^d   Newman, Daniel R ^d   Williams, D'Nyce L ^e   Jamieson, Denise J ^e  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNC MAD   (Madagascar)

^d NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^e University of North Carolina at Chapel Hill ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDFORM; HYDROXYETHYLCELLULOSE; MICROBICIDE; PLACEBO; UNCLASSIFIED DRUG; TOPICAL ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; ASTHMA; BURNING SENSATION; CLINICAL TRIAL; CONDOM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM INFECTION; DRUG FEVER; DRUG INDUCED HEADACHE; EXPERIMENTAL STUDY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GEL; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; INFLAMMATION; INFLUENZA; MADAGASCAR; NORMAL HUMAN; PELVIS PAIN SYNDROME; POLLAKISURIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SEXUAL BEHAVIOR; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; UROGENITAL TRACT INFECTION; UTERINE CERVIX CAP; VAGINA DISCHARGE; VAGINAL IRRITATION; FEMALE CONTRACEPTIVE DEVICE; MIDDLE AGED; PATIENT ATTITUDE; PATIENT COMPLIANCE; PILOT STUDY; REGRESSION ANALYSIS; SAFE SEX; UTILIZATION REVIEW; WOMEN'S HEALTH;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS, LOCAL; CONDOMS; CONTRACEPTIVE DEVICES, FEMALE; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; PILOT PROJECTS; REGRESSION ANALYSIS; SAFE SEX; SEXUALLY TRANSMITTED DISEASES; WOMEN'S HEALTH;

EID: 53749084426     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e318175d8ab     Document Type: Article

References (50)

1. Mabey D, Mayaud P. Approaches to the control of sexually transmitted infections in developing countries: Old problems and modern challenges. Sex Transm Infect 2004; 80:174-182.
2. Glasier A, Gulmezoglu AM, Schmid GP, et al. Sexual and reproductive health: A matter of life and death. Lancet 2006; 368:1595-1607.
3. Behets FM, Rasolofomanana JR, Van Damme K, et al. Evidence-based treatment guidelines for sexually transmitted infections developed with and for female sex workers. Trop Med Int Health 2003; 8:251-258.
4. Feldblum PJ, Hatzell T, Van Damme K, et al. Results of a randomised trial of male condom promotion among Madagascar sex workers. Sex Transm Infect 2005; 81:166-173.
5. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: The contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75:3-17.
6. Cohen MS. Sexually transmitted diseases enhance HIV transmission: No longer a hypothesis. Lancet 1998; 351:5-7.
7. Corbett EL, Steketee RW, ter Kuile FO, et al. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet 2002; 359:2177-2187.
8. The Madagascar Action Plan 2007-2012. Available at: http://www. madagascar-presidency.gov.mg/MAP/?id=56&idy=23&lang = 1.
9. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004; 82:454-461.
10. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 2004; 10:315-336.
11. Stein ZA. HIV prevention: The need for methods women can use. Am J Public Health 1990; 80:460-462.
12. Maher JE, Harvey SM, Bird ST, et al. Acceptability of the vaginal diaphragm among current users. Perspect Sex Reprod Health 2004; 36:64-71.
13. Bird ST, Harvey SM, Maher JE, et al. Acceptability of an existing, female-controlled contraceptive method that could potentially protect against HIV: A comparison of diaphragm users and other method users. Womens Health Issues 2004; 14:85-93.
14. Minnis AM, Padian NS. Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: Current evidence and future research directions. Sex Transm Infect 2005; 81:193-200.
15. Moench TR, Chipato T, Padian NS. Preventing disease by protecting the cervix: The unexplored promise of internal vaginal barrier devices. AIDS 2001; 15:1-8.
16. Rosenberg MJ, Davidson AJ, Chen JH, et al. Barrier contraceptives and sexually transmitted diseases in women: A comparison of female-dependent methods and condoms. Am J Public Health 1992; 82:669-674.
17. Austin H, Louv WC, Alexander WJ. A case-control study of spermicides and gonorrhea. JAMA 1984; 251:2822-2824.
18. Magder LS, Harrison HR, Ehret JM, et al. Factors related to genital Chlamydia trachomatis and its diagnosis by culture in a sexually transmitted disease clinic. Am J Epidemiol 1988; 128:298-308.
19. Becker TM, Wheeler CM, McGough NS, et al. Contraceptive and reproductive risks for cervical dysplasia in southwestern Hispanic and non-Hispanic white women. Int J Epidemiol 1994; 23:913-922.
20. Wolner-Hanssen P, Eschenbach DA, Paavonen J, et al. Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use. JAMA 1990; 263:54-59.
21. Kelaghan J, Rubin GL, Ory HW, et al. Barrier-method contraceptives and pelvic inflammatory disease. JAMA 1982; 248:184-187.
22. Padian NS, van der Straten A, Ramjee G, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: A randomised controlled trial. Lancet 2007; 370:251-261.
23. De Bruyn G, Shiboski S, Ramjee G, et al. The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: Results of a randomized controlled trial. Abstract O-5, International Society for Sexually Transmitted Disease Research (ISSTDR) Annual Meeting; July 29-August 1, 2007; Seattle.
24. McGowan I. Microbicides: A new frontier in HIV prevention. Biologicals 2006; 34:241-255.
25. Luchters S, Chersich MF, Jao I, et al. Acceptability of the diaphragm in Mombasa Kenya: A 6-month prospective study. Eur J Contracept Reprod Health Care 2007; 12:345-353.
26. Behets F, Norris Turner A, Van Damme K, et al. Acceptability and feasibility of continuous diaphragm use among sex workers in Madagascar. Sex Trans Inf 2005; 81:472-476.
27. van der Straten A, Kang MS, Posner SF, et al. Predictors of diaphragm use as a potential sexually transmitted disease/HIV prevention method in Zimbabwe. Sex Transm Dis 2005; 32:64-71.
28. Coggins C, Blanchard K, Alvarez F, et al. Preliminary safety and acceptability of a Carrageenan gel for possible use as a vaginal microbicide. Sex Transm Infect 2000; 76:480-483.
29. Mauck CK, Weiner DH, Ballagh SA, et al. Single and multiple exposure tolerance study of polystyrene sulfonate gel: A phase I safety and colposcopy study. Contraception 2004; 70:77-83.
30. Mantell JE, Myer L, Carballo-Dieguez A, et al. Microbicide acceptability research: Current approaches and future directions. Soc Sci Med 2005; 60:319-330.
31. Moon MW, Khumalo-Sakutukwa GN, Heiman JE, et al. Vaginal microbicides for HIV/STI prevention in Zimbabwe: What key informants say. J Transcult Nurs 2002; 13:19-23.
32. Garg S, Anderson R, Chany C, et al. Properties of a new acid-buffering bioadhesive vaginal formulation (Acidform). Contraception 2001; 64:67-75.
33. AcidForm Investigator's Brochure, 2005.
34. Tuyama AC, Cheshenko N, Carlucci MJ, et al. ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: Optimal candidate for microbicide combinations. J Infect Dis 2006; 194:795-803.
35. Spencer SE, Valentin-Bon IE, Whaley K, et al. Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model. J Infect Dis 2004; 189:410-419.
36. Tabet SR, Callahan MM, Mauck CK, et al. Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men. J Acquir Immun Defic Syndr 2003; 33:476-483.
37. Schwartz JL, Poindexter A, Schmitz SW, et al. Male tolerance of ACIDFORM gel. Contraception 2005; 71:443-446.
38. Amaral E, Perdigao A, Souza MH, et al. Vaginal safety after use of a bioadhesive, acid-buffering, microbicidal contraceptive gel (ACIDFORM) and a 2% nonoxynol-9 product. Contraception 2006; 73: 542-547.
39. Amaral E, Faundes A, Zaneveld L, et al. Study of the vaginal tolerance to acidform, an acid-buffering, bioadhesive gel. Contraception 1999; 60:361-366.
40. Williams DL, Creinin MD, Barnhart K, et al. Safety Analysis of the diaphragm in combination with vaginal microbicide gels (ACIDFORM and BufferGel): Results of a 14 Day Trial. Abstract # OB21, Microbicides 2006, Cape Town, South Africa, April 24-26, 2006.
41. Schwartz J, Lai J, Creinin M, et al. Fourteen day safety and acceptability study of ACIDFORM Gel: A randomized phase I safety study. Abstract # OB4, Microbicides 2006, Cape Town, South Africa, April 24-26, 2006.
42. Williams DL, Newman DR, Ballagh SA, et al. Phase I safety trial of two vaginal microbicide gels (Acidform or BufferGel) used with a diaphragm compared to KY jelly used with a diaphragm. Sex Transm Dis 2007; 34:977-984.
43. Trifonova RT, Pasicznyk JM, Fichorova RN. Biocompatibility of solid-dosage forms of anti-HIV-1 microbicides with the human cervico-vaginal mucosa modeled ex vivo. Antimicrob Agents Che- mother 2006; 50:4005-4010.
44. Tien D, Schnaare RL, Kang F, et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 2005; 21:845-853.
45. Schwartz J, Ballagh S, Kwok C, et al. Fourteen-day safety and acceptability study of the HEC-based universal placebo gel. Abstract # PB68, Microbicides 2006, Cape Town, South Africa, April 24-26, 2006.
46. Pettifor AE, Turner AN, Van Damme K, et al. Increased risk of chlamydial and gonococcal infection in adolescent sex workers in Madagascar. Sex Transm Dis 2007; 34:475-478.
47. Lachin JM. Statistical considerations in the intent-to-treat principle. Control Clin Trials 2000; 21:167-89.
48. Legardy-Williams J, Bell A, Jamieson D, et al. Attitudes and beliefs about vaginal cleansing among women, men, and healthcare providers in Antananarivo, Madagascar. Abstract # OC19, Microbicides 2006, Cape Town, South Africa, April 24-26, 2006.
49. Family Health International press release. "Phase 3 Trial in Nigeria Evaluating the Effectiveness of SAVVY Gel in Preventing HIV Infection in Women Will Close" (August 28, 2006). Available at: http://www.fhi.org/en/ AboutFHI/Media/Releases/Phase3SAVVY082806.htm. Accessed December 4, 2007.
50. Kaul R, Kimani J, Nagelkerke NJ, et al. Reduced HIV risk-taking and low HIV incidence after enrollment and risk-reduction counseling in a sexually transmitted disease prevention trial in Nairobi, Kenya. J Acquir Immune Defic Syndr 2002;30:69-72.